Perspective Therapeutics (CATX) Morgan Stanley 24th Annual Global Healthcare Conference summary

Industry landscape and innovation

• Radiopharmaceuticals offer a new therapeutic approach by delivering targeted radiation as a drug, minimizing damage to healthy tissue and enabling combination with other oncology modalities.

• Lead-212 was chosen for its optimal half-life and imaging capabilities, overcoming historical supply and chelation challenges through proprietary technology.

• Over 400 lead-212 generators have been shipped globally, with more than 150 patients treated and first-in-human imaging achieved in the past year.

• Theranostic pairing with lead-203 enables precise patient selection and dosimetry, improving confidence in treatment outcomes.

• Manufacturing and isotope supply are scalable, with regional facilities and stockpiling strategies reducing supply chain risk.

Lead programs and clinical progress

• VMT-α-NET targets neuroendocrine tumors, aiming to surpass existing beta-emitter therapies like LUTATHERA with higher potency and safety.

• Fast Track designation has been granted, with strong physician engagement and promising early data showing 40%-50% response rates and durable disease control.

• Safety profile is notable, with no Grade 4/5 adverse events or dose-limiting toxicities observed to date.

• Phase III site activation is targeted for year-end, with ongoing regulatory engagement and a focus on real-world control arms.

• Expansion into SSTR2-positive meningioma could double the addressable market for SSTR2 agents.

Pipeline expansion and strategic focus

• VMT01 in melanoma leverages MC1R targeting, with early data showing strong responses in receptor-positive, heavily pretreated patients.

• Combination studies with checkpoint inhibitors are underway, with the rationale that lead-212’s short emission window avoids immune suppression seen with other isotopes.

• FAP-targeted programs address a broad range of solid tumors, with imaging and therapeutic agents showing strong tumor accumulation and potential for rapid approval in select indications.

• Strategic collaborations, such as with pembrolizumab, are being pursued to accelerate development in high-priority tumor types.

• The platform’s flexibility allows for rapid expansion into new targets and indications, supported by a robust patent portfolio and scalable manufacturing.